Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression [CITEseq]

ABSTRACT: A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression [CITEseq]

PROVIDER: PRJNA1066323 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression

Project description:A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression

| PRJNA1066322 | ENA

A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression [scRNAseq_mouse]

Project description:A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression [scRNAseq_mouse]

| PRJNA1066327 | ENA

A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression [scRNAseq_human]

Project description:A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression [scRNAseq_human]

| PRJNA1066324 | ENA

A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression [CITEseq]

Project description:Dendritic cells (cDCs) are essential mediators of anti-tumor immunity. Cancers have developed mechanisms to render DCs dysfunctional within the tumor microenvironment. Utilizing CD63 as a unique surface marker, we demonstrate that mature regulatory DCs (mregDCs) suppress DC antigen cross-presentation while driving TH2 and regulatory T cell differentiation within tumor-draining lymph node tissues. Transcriptional and metabolic studies show that mregDC functionality is dependent upon the mevalonate biosynthetic pathway and the master transcription factor, SREBP2. Melanoma-derived lactate activates DC SREBP2 in the tumor microenvironment (TME) and drives mregDC development from conventional DCs. DC-specific genetic silencing and pharmacologic inhibition of SREBP2 promotes anti-tumor CD8+ T cell activation and suppresses melanoma progression. CD63+ mregDCs reside within the sentinel lymph nodes of melanoma patients. Collectively, this work describes a tumor-driven SREBP2-dependent program that promotes CD63+ mregDC development and function while serving as a promising therapeutic target for overcoming immune tolerance in the TME.

2024-05-13 | GSE253586 | GEO

A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression [Spatial transcriptomics]

Project description:A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression [Spatial transcriptomics]

| PRJNA1066326 | ENA

A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression [scATAC-seq]

Project description:A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression [scATAC-seq]

| PRJNA1066325 | ENA

A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression [scRNAseq_mouse]

2024-05-13 | GSE253592 | GEO

A Lactate-induced SREBF2-dependent genetic program drives an immunotolerant dendritic cell population during cancer progression [scRNAseq_human]

2024-05-13 | GSE253590 | GEO